Fig. 4.

Outgrowth of TC-1 tumor and survival of C57BL/6 mice after vaccination with different virosome SLP formulations. Tumor outgrowth in mice (n = 8/group) inoculated with TC-1 cells on day 0, randomized for tumor growth and vaccinated on day 8, and again vaccinated on day 22, using the vaccine preparations indicated. Mice were killed when the tumors reached 500 mm³ or after 80 days. Kaplan–Meier graphs of survival: Significant differences (log rank test): both virosome groups vs. untreated animals (p < 0.0001) and Amplivant-SLP virosomes vs. Amplivant-SLP: P < 0.0001, lipid-SLP virosomes plus adjuvants vs. Amplivant-SLP: p = 0.0011. Other comparisons: Amplivant-SLP virosomes vs. lipid-conjugated virosomes with QS-21 and 3D-PHAD: p = 0.7435 Amplivant-SLP virosomes vs. SLP + Montanide conjugated SLP: p = 0.057 Lipid-conjugated virosomes with adjuvants vs. SLP + CpG + Montanide: p = 0.2042. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001